Cardiovascular disease among people living with HIV in Brazil

Imagem de Miniatura
Arquivos
art_BOETTIGER_Cardiovascular_disease_among_people_living_with_HIV_in_2020.PDF.pdf (239.92 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
BOETTIGER, David C.
ESCUDER, Maria Mercedes
LAW, Matthew G.
VELOSO, Valdilea
SOUZA, Rosa A.
IKEDA, Maria L. R.
ALENCASTRO, Paulo R. de
TUPINAMBAS, Unai
BRITES, Carlos
GRINSZTEJN, Beatriz
Citação
TROPICAL MEDICINE & INTERNATIONAL HEALTH, v.25, n.7, p.886-896, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil. Methods Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014. Results Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9-4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR] 6.4 for >= 55 years vs. <35 years, 95% CI: 2.5-16.3, P < 0.01), black race (aHR 1.8 vs. white race, 95% CI: 1.0-3.1, P = 0.04), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4-6.2, P < 0.01), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0-3.1, P = 0.04), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0-14.6, P < 0.01), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2-5.0, P = 0.02) and low nadir CD4 cell count (aHR 1.8 for 100-250 cells/mm(3) vs. >250 cells/mm(3), 95% CI: 1.0-3.2, P = 0.05). The rate of death was 16.6 (95% CI: 15.1-18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1-2.7, P = 0.01). Conclusions Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.
Palavras-chave
HIV, cardiovascular disease, mortality, Brazil, antiretroviral therapy
URI
https://observatorio.fm.usp.br/handle/OPI/37058
Referências
  1. Bedimo RJ, 2011, CLIN INFECT DIS, V53, P84, DOI 10.1093/cid/cir269
  2. Bijker R, 2019, HIV MED, V20, P183, DOI 10.1111/hiv.12687
  3. Bronnum-Hansen H, 2001, STROKE, V32, P2131, DOI 10.1161/hs0901.094253
  4. Brothers CH, 2009, JAIDS-J ACQ IMM DEF, V51, P20, DOI 10.1097/QAI.0b013e31819ff0e6
  5. Brouwer ES, 2014, EPIDEMIOLOGY, V25, P406, DOI 10.1097/EDE.0000000000000041
  6. Castilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233
  7. Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16
  8. Cruciani M, 2011, AIDS, V25, P1993, DOI 10.1097/QAD.0b013e328349c6ee
  9. Desai M, 2015, CLIN INFECT DIS, V61, P445, DOI 10.1093/cid/civ316
  10. Diaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4
  11. Ding X, 2012, JAIDS-J ACQ IMM DEF, V61, P441, DOI 10.1097/QAI.0b013e31826f993c
  12. Drozd DR, 2017, JAIDS-J ACQ IMM DEF, V75, P568, DOI 10.1097/qai.0000000000001450
  13. Duncan Bruce Bartholow, 2017, Rev. bras. epidemiol., V20, P90, DOI 10.1590/1980-5497201700050008
  14. Elion RA, 2018, JAIDS-J ACQ IMM DEF, V78, P62, DOI [10.1097/qai.0000000000001642, 10.1097/QAI.0000000000001642]
  15. Friis-Moller N, 2016, EUR J PREV CARDIOL, V23, P214, DOI 10.1177/2047487315579291
  16. Grangeiro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095673
  17. Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
  18. Lorgis L, 2013, CIRCULATION, V127, P1767, DOI 10.1161/CIRCULATIONAHA.113.001874
  19. Mahajan AP, 2008, AIDS, V22, pS67, DOI 10.1097/01.aids.0000327438.13291.62
  20. Malta DC, 2016, SAO PAULO MED J, V134, P163, DOI 10.1590/1516-3180.2015.02090911
  21. Malta DC, 2015, SAO PAULO MED J, V133, P286, DOI 10.1590/1516-3180.2015.13340308
  22. Nauta ST, 2012, DIABETES CARE, V35, P2043, DOI 10.2337/dc11-2462
  23. Obel N, 2010, HIV MED, V11, P130, DOI 10.1111/j.1468-1293.2009.00751.x
  24. Sabin CA, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0588-4
  25. Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9
  26. Schmidt M, 2016, CIRC-CARDIOVASC QUAL, V9, P523, DOI 10.1161/CIRCOUTCOMES.115.002661
  27. Schmidt M, 2014, NEUROLOGY, V82, P340, DOI 10.1212/WNL.0000000000000062
  28. Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369
  29. Smolina K, 2012, CIRC-CARDIOVASC QUAL, V5, P532, DOI 10.1161/CIRCOUTCOMES.111.964700
  30. Walker RW, 2013, LANCET GLOB HEALTH, V1, pE282, DOI 10.1016/S2214-109X(13)70068-8
  31. Zanni MV, 2012, CURR HIV-AIDS REP, V9, P200, DOI 10.1007/s11904-012-0123-y

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03